Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

PAVmed (PAVM) EBIAT (2021 - 2025)

PAVmed has reported EBIAT over the past 5 years, most recently at -$1.3 million for Q4 2025.

  • Quarterly results put EBIAT at -$1.3 million for Q4 2025, up 91.51% from a year ago — trailing twelve months through Dec 2025 was -$975000.0 (up 98.33% YoY), and the annual figure for FY2025 was $401000.0, down 98.99%.
  • EBIAT for Q4 2025 was -$1.3 million at PAVmed, up from -$6.0 million in the prior quarter.
  • Over the last five years, EBIAT for PAVM hit a ceiling of $18.6 million in Q1 2025 and a floor of -$34.7 million in Q4 2022.
  • Median EBIAT over the past 5 years was -$14.9 million (2024), compared with a mean of -$14.2 million.
  • Biggest five-year swings in EBIAT: plummeted 122.52% in 2022 and later surged 222.42% in 2025.
  • PAVmed's EBIAT stood at -$17.2 million in 2021, then plummeted by 101.62% to -$34.7 million in 2022, then skyrocketed by 49.85% to -$17.4 million in 2023, then increased by 14.56% to -$14.9 million in 2024, then soared by 91.51% to -$1.3 million in 2025.
  • The last three reported values for EBIAT were -$1.3 million (Q4 2025), -$6.0 million (Q3 2025), and -$12.3 million (Q2 2025) per Business Quant data.